Biopeople

Strengthening Management

Strengthening Management

25.03.2013 - Swiss Cytos Biotechnology Ltd (Schlieren) has strengthened its Board with two appointments.

Matthias Alder will become Executive Vice President for Corporate Development and Legal Affairs and Cheryl Lassen will follow Philipp Mueller as Vice President for Clinical Development, who will retire at the end of March 2013. Matthias Alder brings in more than 19 years of experience in the pharmaceutical and biotechnology sector. He comes in from Micromet, where he was Senior VP Administration, General Counsel and Secretary. Previousy he worked with Cooley LLP, as in-house counsel at Ciba-Geigy and Novartis. Cheryl Lassen, MD, joins bringing a wealth of clinical development experience, with particular expertise in respiratory diseases. Dr. Lassen joins Cytos from Novartis where she was Program Leader. In her 20 year career, she has worked on a multitude of clinical development programs and in medical affairs in the UK and in South Africa for companies including Bristol Myers Squibb, Abbott Laboratories and Pharmacia.

http://www.european-biotechnology-news.com/people/bio-people/2013-01/cheryl-lassen.html

17.09.2013 In early September Carsten Hellmann was appointed Executive Vice-President of Merial, Sanofi’s animal health business.

He was joining the French giant from Danish Chr. Hansen Holding A/S, where he has been Executive VP Global Sales since 200The business expert is a former CEO of Nunc A/S, and in the past has held several managerial roles in both the pharmaceutical and medtech industries.

12.09.2013 French food safety expert Catherine Geslain-Lanéelle has resigned from her post as Executive Director of the European Food Safety Authority.

She takes up a post as Director General for agricultural, agri-food and territorial policies at the French agriculture ministry. Catherine Geslain-Laneelle has lead the authority since July 2006, and was previously one of the two Vice-Chairs of EFSA’s Management Board. She has been working in the area of food safety since 1991, when she first joined the European Commission as a National Expert at DG Industry and Internal Market. 

13.09.2013 London-based Skyepharma plc in late August named Andrew Derodra as its new CFO.

The finance expert follows Peter Grant, who was appointed Chief Executive Officer in January 2012 and has retained responsibility for financial affairs. Derodra will join the company in the last quarter of 2013. He joins Skyepharma from Tate & Lyle, where he has been Group Vice President Finance and Control since 2011. The new CFO has spent 23 years working in senior finance roles at five FTSE100 groups, among them SAB Miller, Diageo, British Airways and Reed Elsevier.

02.09.2013 Sir David Lane, the man behind the discovery of the p53 tumour suppressor

protein, has joined the Ludwig Institute for Cancer Research as its Scientific Director.

In this role, Professor Lane will lead Ludwig's global cancer research effort. Lane came in from Singapore's Agency for Science, Technology and Research (A*STAR). He will retain his existing appointment at A*STAR and share his time between Ludwig and A*STAR. He succeeds Andrew Simpson, PhD, who served for five years as Ludwig's Scientific Director between 2007 and 2012. While carrying out his responsibilities at A*Star, Professor Lane also served as Cancer Research UK's first Chief Scientist. His contributions to cancer research have been widely recognised. He was knighted by Queen Elizabeth II in 2000 and most recently received the 2012 Cancer Research UK Lifetime Achievement Prize. The immunologist is a member of European Molecular Biology Organization (EMBO) and a Fellow of the Royal Society, the UK's premier scientific academy. He is the author or co-author of more than 350 publications in international peer-reviewed journals.

05.09.2013 Biologics and Fine chemicals manufacturer Novasep has named Christian Thiry

as its new Chief Financial Officer (CFO).

Thiry joins Novasep bringing 30 years of experience in audit and finance executive Management in the life sciences sector. For the last 12 years he served as CFO and group executive committee member of Stallergenes.

09.09.2013 Belgian-Swiss biomarker expert Biocartis has strengthened its management

with Ulrik Cordis as new Chief Commercial Officer.

The biochemist joins Biocartis from Thermo Fisher Scientific, where he held the position of Global Sales & Marketing Director in Slides & Specialty Glass. Cordis previously worked with companion and cancer diagnostics giant DAKO A/S and started his career with Pharmacia Biotech A/S (now part of GE Healthcare) in 1995. He received his Master of Science in Biochemistry from the University of Copenhagen and holds a Bachelor of Commerce (HD) from Copenhagen Business School.

15.08.2013 Ten years ago, Thomas Schinecker began his career at Roche. In July, the former President of Roche's (now closed) Next Generation Sequencing arm 454 Life Sciences became General Manager of Roche Diagnostics.

He follows Jürgen Redmann, who stepped down after more than three and a half decades with the Swiss giant. The bio-chemist began working for Roche as a product manager in the firm's Basel headquarters, became Head of Marketing & Sales Austria in 2005, then led Roche Diagnostics Sweden from 2008-2011 before joining 454 Life Sciences.

19.08.2013 Oxford-based inhaled biopharma developer Prosonix plc has appointed Frank Condella as its Non-executive Director.

The pharmacist has over 30 years of business experience, including senior leadership roles in both privately and publicly held companies in the healthcare industry - particularly in the development and commercialisation of respiratory medicines. Currently, Condella is President and Chief Executive Officer of Columbia Laboratories Inc. - a NASDAQ-listed speciality pharmaceutical company - and Non-executive Chairman of Skye-pharma plc, a London-listed speciality drug delivery company. Condella was CEO of Skye-pharma from 2006-2008, President of European Operations and Managing Director UK at IVAX Corporation from 2002-2006, as well as President and CEO of Faulding Pharmaceutical Co. from 2000-2001. Previously, he was Vice-President of Specialty Care Products at Roche and VP and General Manager of the Lederle unit of American Home Products.

21.08.2013 Vascular medical technology specialist Lombard Medical Technologies plc has hired Raymond Wayne Cohen as its Non-executive Chairman.

Cohen is also currently Non--executive Chairman of Jenavalve Technology, Syncroness, Spectrum Pharmaceuticals, and Non-executive Director at Bio-Life Solutions and Lone-Star Heart. He comes in from Vessix Vascular, where he was CEO.

06.08.2013 Imperial Innovations Group plc has appointed Russ Cummings as its new CEO to replace Susan Searle, who has stepped down. Cummings has been the group's Chief Investment Officer and a director since its flotation in 2006.

Prior to his career at the technology commercialisation and investment group, the mechanical engineer worked at Scottish Equity Partners as a director in the Information Technology Group, as well as at 3i Group and with Royce Motors.

Vorherige Seite3/8Nächste Seite

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014


Current issue

All issues

Product of the week

Products